Your browser is no longer supported

For the best possible experience using our website we recommend you upgrade to a newer version or another browser.

Your browser appears to have cookies disabled. For the best experience of this website, please enable cookies in your browser

We'll assume we have your consent to use cookies, for example so you won't need to log in each time you visit our site.
Learn more

NICE questions new diabetes drug’s cost effectiveness  

  • Comment

The National Institute for Health and Care Excellence has called for more evidence from Boehringer Ingelheim on its drug empagliflozin for treating type 2 diabetes.

Empagliflozin (Jardiance) is an oral, once-daily medication belonging to a class of drugs called sodium glucose co-transporter (SGLT-2) inhibitors.

It works by blocking the reabsorption of glucose in the kidneys, which is instead passed out of the body in the urine.

In latest draft guidance, NICE said it could not recommend the drug for use on the NHS without more evidence that it would be a cost-effective treatment.  

Professor Carole Longson, director of the NICE Centre for Health Technology Evaluation, said it was “important to have a varied arsenal” to tackle diabetes.

“New treatments, like empagliflozin, will help clinicians give people with type 2 diabetes the right treatment,” she said.

Professor Carole Longson

Professor Carole Longson

“There is good evidence which shows that empagliflozin is clinically effective,” she said. “But we need more information to demonstrate that it is cost-effective when compared with other treatments the NHS already provides.

“The [NICE] committee has requested more information to help it decide whether empagliflozin is a cost-effective use of NHS resources,” she added.

According to the company’s submission to NICE, the price of empagliflozin is £36.59 per pack of 28 tablets for both 10 mg and 25 mg doses. The annual cost is estimated to be £470.30.

The recommended starting dosage is 10 mg once daily for both monotherapy and as an add-on combination therapy with other glucose lowering medicinal products including insulin.

The draft guidance will be available on the NICE website for consultation from 27 August.

  • Comment

Have your say

You must sign in to make a comment

Please remember that the submission of any material is governed by our Terms and Conditions and by submitting material you confirm your agreement to these Terms and Conditions. Links may be included in your comments but HTML is not permitted.

Related Jobs